Dr. Voichita Bar Ad, MD

Dr. Bar Ad practices at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Bar Ad's NPI, 1730135393, was assigned on May 25, 2006. Dr. Bar Ad holds Pennsylvania license MD428235.

Dr. Bar Ad's primary practice is Thomas Jefferson University Hospital, at 111 South 11th Street, Philadelphia, PA 19107 in Philadelphia County. The practice phone is (215) 955-6000.

Dr. Bar Ad's primary practice is Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, part of Thomas Jefferson University. The medical group on file is Jefferson University Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bar Ad practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Bar Ad's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Bar Ad is licensed in Pennsylvania.

CMS data shows 1,743 Medicare services from Dr. Bar Ad across 16 procedure codes in 2024, for 208 Medicare patients. Medicare paid $120,532 for them.

CMS counts 208 Medicare patients who saw Dr. Bar Ad in 2024. The largest group is 65 to 74, with 112 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bar Ad's median patient age at 65, with 42% women.

In 2024, Dr. Bar Ad wrote 39 Medicare Part D claims for 23 patients. 92% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $32 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

Dr. Bar Ad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bar Ad as offering telehealth.

Dmand AI links 11 papers to Dr. Bar Ad, published from 2011 to 2021. 2015 was the busiest year, with 2. The most frequent topics are Head and Neck Neoplasms, Internship and Residency and Models, Statistical. Dr. Bar Ad has published most often in J Neurooncol. Dr. Bar Ad's most frequent co-authors are David W. Andrews, MD, Deepak Bhamidipati and David Michael Cognetti, MD.

Dmand AI links Dr. Bar Ad to 8 clinical trials, 3 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Ependymoma and Oropharyngeal Neoplasms. Sidney Kimmel Cancer Center at Thomas Jefferson University sponsors the most, 6.

CMS Open Payments shows 11 general payments to Dr. Bar Ad from 5 drug and device companies from 2017 to 2024. Food and beverage make up the largest share, 83% of the total. IsoRay, Inc paid the most, $331.